GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PROCEPT BioRobotics Corp (NAS:PRCT) » Definitions » Net Current Asset Value

PROCEPT BioRobotics (PROCEPT BioRobotics) Net Current Asset Value : $4.09 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is PROCEPT BioRobotics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

PROCEPT BioRobotics's net current asset value per share for the quarter that ended in Mar. 2024 was $4.09.

The historical rank and industry rank for PROCEPT BioRobotics's Net Current Asset Value or its related term are showing as below:

PRCT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.26   Med: 9.4   Max: 16.83
Current: 16.67

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of PROCEPT BioRobotics was 16.83. The lowest was 4.26. And the median was 9.40.

PRCT's Price-to-Net-Current-Asset-Value is ranked worse than
81.34% of 584 companies
in the Medical Devices & Instruments industry
Industry Median: 4.95 vs PRCT: 16.67

PROCEPT BioRobotics Net Current Asset Value Historical Data

The historical data trend for PROCEPT BioRobotics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PROCEPT BioRobotics Net Current Asset Value Chart

PROCEPT BioRobotics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
-4.62 -5.65 5.87 3.58 4.46

PROCEPT BioRobotics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.98 2.51 4.89 4.46 4.09

Competitive Comparison of PROCEPT BioRobotics's Net Current Asset Value

For the Medical Devices subindustry, PROCEPT BioRobotics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PROCEPT BioRobotics's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where PROCEPT BioRobotics's Price-to-Net-Current-Asset-Value falls into.



PROCEPT BioRobotics Net Current Asset Value Calculation

PROCEPT BioRobotics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(350.567-123.965-0-0)/50.771
=4.46

PROCEPT BioRobotics's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2024 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(329.186-118.853-0-0)/51.393
=4.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PROCEPT BioRobotics  (NAS:PRCT) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


PROCEPT BioRobotics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of PROCEPT BioRobotics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


PROCEPT BioRobotics (PROCEPT BioRobotics) Business Description

Traded in Other Exchanges
N/A
Address
900 Island Drive, Redwood, CA, USA, 94065
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
Executives
Alaleh Nouri officer: SVP, GEN COUNSEL, CORP. SEC. 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Kevin Waters officer: Senior VP, CFO 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Frederic H Moll director C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
Wood Morgan Colby director C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CA 94065
Reza Zadno director, officer: President, CEO 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Hisham Shiblaq officer: SVP, Commercial Operations C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Thomas M Krummel director C/O CALIFORNIA WATER SERVICE GROUP, 1720 N. FIRST STREET, SAN JOSE CA 95118
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 88 Llc 10 percent owner 55 RAILROAD AVE, GREENWICH CT 06830
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901